SELLAS Life Sciences (SLS) Debt to Equity (2013 - 2018)
SELLAS Life Sciences (SLS) reported Debt to Equity of $0.0 for Q3 2018, down 99.5% year-over-year from $0.83 in Q3 2017, and up 100.13% quarter-over-quarter from -$3.13 in Q2 2018.
SELLAS Life Sciences (SLS) Debt to Equity (2013 - 2018) Analysis & Trends
SELLAS Life Sciences (SLS) has 6 years of Debt to Equity data on file, last reported at $0.0 in Q3 2018.
- Debt to Equity for Q3 2018 came in at $0.0, down 99.5% year-over-year; the trailing twelve-month figure through Sep 2018 was $0.0 (down 99.5% YoY), and the FY2017 annual result was $5.31, up 1652.09% from the prior year.
- Debt to Equity rose to $0.0 in Q3 2018 per SLS's latest filing, from -$3.13 in the prior quarter.
- Over five years, Debt to Equity peaked at $5.31 in Q4 2017 and troughed at -$7.34 in Q1 2018.
- A 5-year average of $0.0 and a median of $0.23 in 2014 frame the typical range for Debt to Equity.
- The sharpest annual moves came in 2017 and 2018: Debt to Equity soared 1652.09% in 2017, then sank 1684.84% in 2018.
- A 5-year view of Debt to Equity shows it stood at $0.23 in 2014, then plunged by 270.47% to -$0.39 in 2015, then gained by 11.51% to -$0.34 in 2016, then soared by 1652.09% to $5.31 in 2017, then plunged by 99.92% to $0.0 in 2018.
- Business Quant data shows SLS's Debt to Equity at $0.0 in Q3 2018, -$3.13 in Q2 2018, and -$7.34 in Q1 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.32 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | SELLAS Life Sciences | 1.39 Bn | 1.39 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | 0.00 |
| Jun 30, 2018 | -3.13 |
| Mar 31, 2018 | -7.34 |
| Dec 31, 2017 | 5.31 |
| Sep 30, 2017 | 0.83 |
| Jun 30, 2017 | 0.68 |
| Mar 31, 2017 | 0.46 |
| Dec 31, 2016 | -0.34 |
| Sep 30, 2016 | 0.99 |
| Jun 30, 2016 | 1.14 |
| Mar 31, 2016 | 0.30 |
| Dec 31, 2015 | -0.39 |
| Sep 30, 2015 | 0.18 |
| Jun 30, 2015 | 0.13 |
| Mar 31, 2015 | 0.13 |
| Dec 31, 2014 | 0.23 |
| Sep 30, 2014 | 0.30 |
| Jun 30, 2014 | 0.36 |
| Mar 31, 2014 | 0.21 |
| Dec 31, 2013 | 1.68 |